Journal of the Renin-angiotensin-aldosterone System

The Journal of the Renin-Angiotensin-Aldosterone System is a quarterly peer-reviewed journal devoted to the renin-angiotensin-aldosterone system and other peptidergic systems, founded in 2000 and published by SAGE, with a 2025 impact factor of 10.6（Journal of the Renin-Angiotensin-Aldosterone System）是一本致力于肾素-血管紧张素-醛固酮系统及其他肽能系统的季刊同行评审期刊，2000 年创刊并由（SAGE）出版，2025 年影响因子为 10.6。

Scope

• The journal focuses on the normal and abnormal function of the renin-angiotensin-aldosterone system and on its pharmacology and therapeutics该刊聚焦肾素-血管紧张素-醛固酮系统的正常与异常功能及其药理学与治疗学。
• Coverage is mostly cardiovascular but extends to all areas where the system is present, including the brain, the lungs, and the gastro-intestinal tract研究以心血管领域为主，同时涵盖该系统存在的所有部位，包括脑、肺与胃肠道。
• The journal also publishes research on other peptides, such as vasopressin, the natriuretic peptides, and the kallikrein-kinin system该刊还发表关于其他肽类的研究，如血管加压素、利钠肽与激肽释放酶-激肽系统。
• It serves as a resource for biomedical professionals, including basic scientists and clinicians, primarily with an active interest in the system in humans and other mammals该刊为生物医学专业人士提供资源，其主要读者为对人与其他哺乳动物中该系统抱有深入兴趣的基础科学家与临床医生。
• Article types include review articles, original articles presented as full-length reports or short communications, case reports, and letters文章类型包括综述、以全长报告或短篇通信形式呈现的原创论文、病例报告与读者来信。
• The journal is online-only, and optional open access publishing is available through the Sage Choice program该刊仅在线出版，并可通过（Sage Choice）项目选择性实现开放获取。

History

• The journal was founded in 2000, and its founding editors were Peter Sever of Imperial College London and Graham MacGregor, then at St George's University of London该刊于 2000 年创办，创刊主编为伦敦帝国理工学院的（Peter Sever）与当时任职于（St George's University of London）的（Graham MacGregor）。^[1]
• The journal has issued one volume per year since 2000 and reached volume 27 in 2026该刊自 2000 年起每年出版一卷，2026 年已出至第 27 卷。
• Michael Schachter and Christopher Wilcox also served as editors and are now listed as editors emeritus together with Sever and MacGregor（Michael Schachter）与（Christopher Wilcox）也曾担任编辑，现与（Sever）和（MacGregor）一同列为荣誉编辑。
• The journal is a member of the Committee on Publication Ethics and archives its content in CLOCKSS, LOCKSS, PubMed Central, and Portico该刊为国际出版伦理委员会成员，其内容存档于（CLOCKSS）、（LOCKSS）、（PubMed Central）与（Portico）。
• Its impact factor climbed from 1.636 in 2021 to 4.109 in 2022 and 10.6 in 2025, with a five-year impact factor of 4.3其影响因子从 2021 年的 1.636 升至 2022 年的 4.109 与 2025 年的 10.6，五年影响因子为 4.3。
• The journal reports a median of 60 days from submission to acceptance and an acceptance rate of 37.1%该刊公布投稿至接受的中位时间为 60 天，接受率为 37.1%。

Editors

• Chengming Fan, MD, PhD, of the Second Xiangya Hospital of Central South University in China is the Editor中国中南大学湘雅二医院的（Chengming Fan）现任主编，拥有医学博士与哲学博士学位。
• Editors emeritus are Michael Schachter and Peter Sever of Imperial College London, Graham MacGregor of Queen Mary University of London, and Christopher Wilcox of Georgetown University荣誉编辑包括伦敦帝国理工学院的（Michael Schachter）与（Peter Sever）、伦敦玛丽女王大学的（Graham MacGregor）以及乔治城大学的（Christopher Wilcox）。
• The editorial board has thirty-two members, with strong representation from China编委会由 32 位成员组成，其中中国学者占相当比例。
• Board members come from China, India, Iran, Japan, Nigeria, Poland, the United States, and Hong Kong, among them Robert Speth of Nova Southeastern University, Michal Nowicki of Medical University of Lodz, and Lawrence Olatunji of the University of Ilorin编委来自中国、印度、伊朗、日本、尼日利亚、波兰、美国与中国香港等地，包括（Nova Southeastern University）的（Robert Speth）、（Medical University of Lodz）的（Michal Nowicki）与（University of Ilorin）的（Lawrence Olatunji）。
• Manuscripts are assessed by two expert reviewers in a single-anonymized process, and the journal is a member of the Committee on Publication Ethics稿件由两位专家评审人以单匿名方式评审，该刊为国际出版伦理委员会成员。